卓越新能(688196.SH):擬投資10.5億元建生物柴油和生物基增塑劑建設項目
格隆匯1月4日丨卓越新能(688196.SH)公佈,公司於2022年1月1日與龍巖市新羅區人民政府簽訂《卓越新能生物柴油和生物基增塑劑建設項目投資合同書》,約定公司擬投資10.50億元在新羅生物精細化工產業園(卓越新能一期大門東側)建設生物柴油和生物基增塑劑建設項目。
項目總投資10.50億元,實現年產生物柴油和生物基增塑劑20萬噸,預計可新增銷售收入15.00億元,利税2.60億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.